Making decisions to fund novel medicines via the Pharmaceutical Benefits Schedule (PBS) is challenging and complex. As health technologies advance, the Australian Government needs to rely on high-quality independent evidence to support new medicines and update existing listings.

Australia is highly regarded for its rigorous and efficient health technology evaluation system, and the Centre for the Business and Economics of Health (CBEH) is part of this. Our Health Technology Assessment team provides expertise in health economics, epidemiology, and critical reviewing to appraise submissions from pharmaceutical companies seeking government subsidy of a pharmaceutical or vaccine through listing on the PBS. In collaboration with the UQ Centre for Health Services Research, we help empower the Pharmaceutical Benefits Advisory Committee (PBAC) to make informed and objective decisions in the interests of better health.

Project members

Our CBEH team

Profile photo of Dr Haitham Tuffaha

Associate Professor Haitham Tuffaha

Professor
Centre for the Business and Economics of Health

Profile photo of Dr Kim Edmunds

Dr Kim Edmunds

Research Fellow
Centre for the Business and Economics of Health

Profile photo of Hannah Beilby

Hannah Beilby

Research Assistant
Centre for the Business and Economics of Health

person silhouette as a profile image placeholder

Shiksha Arora

Research Assistant
Centre for the Business and Economics of Health


Our collaborators

The University of Queensland Evaluation Services Team (QuEST) delivers this service and is co-led by Associate Professor Haitham Tuffaha from CBEH and Associate Professor Tracy Comans from the Centre for Health Services Research.